AbCellera Biologics Inc (NASDAQ:ABCL) currently has a daily average trading volume of 4.01M but it saw 3671027 shares traded in last market. With a market cap of 712.19M USD, the company’s current market price of $2.39 came rising about 1.70 while comparing to the previous closing price of $2.35. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.83 and as low as $2.11. In the recent trading on the day, stock has struck highest price mark of $2.32 while lowest mark touched by it was $2.43.
Taking a look at 20-day trading activity of AbCellera Biologics Inc (ABCL) gives us an average price of $2.56, while its current price level is -50.52% below from 52-week high level whereas it is 13.27% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.93 while that of 200 days or SMA-200 reads an average of $2.87. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.79% during that period while stretching the period over a month that increases to 7.50%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 40.22 which implies that the stock is in neutral territory.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Hold” on February 22, 2024 while assigning a price target of $9. KeyBanc Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, ABCL’s stock price is moving 1.70% up while it is -30.32% when we observe its performance for the past one month. Year-to-date it is -18.43% down and over the past year, the stock is showing a downside performance of -49.26%.
The company is expected to be releasing its next quarterly report on 2025-Feb-26, for which analysts forecasted an EPS of -0.14 while estimate for next year EPS is -0.66. In next quarter, company is expected to be making quarterly sales of $6.71M as analysts are expecting the sales for current fiscal year at $26.29M and seeing the company making $34.76M in sales next year. Moreover, analysts are in estimates of $7.12M for current-quarter revenue.
Currently, AbCellera Biologics Inc’s total number of outstanding shares is 295.76M with 22.88% of that held by the insiders while 42.47% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -14.58% and return on equity (ROE) at -14.75%. Stock’s beta reads 0.47. Stock has a price to book (P/B) ratio of 0.67 while price to sale or P/S ratio amounts to 24.70. Its return on asset (ROA) is -11.43% on average.
